Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists

October 2019 | Volume 18 | Issue 10 | Original Article | 980 | Copyright © October 2019

Rebeca Teplitz BA,ª Giselle Prado MD,B Graham H. Litchman DO MS,B Darrell S. Rigel MD MSc

ªMedical Student, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY

BClinical Research Fellow, National Society for Cutaneous Medicine, New York, NY

cClinical Professor, Department of Dermatology, NYU School of Medicine, New York, NY

Management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249-261.

10. Migden R, Rischin M, Schmults D, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. New Engl J Med. 2018;379:341-351.

11. Farberg AS, Wysong A, Newman JG, et al. Development of a multi-gene expression profile for recurrence risk prediction in cutaneous squamous cell carcinoma. Poster presented at: American Society for Dermatologic Surgery Annual Meeting; October 14, 2018; Pheonix, AZ.

12. Farberg AS, Glazer AM, White R, et al. Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists' clinical management decisions. J Drugs Dermatol. 2017;16(5):428-431.

13. Ferris LK, Farberg AS, Middlebrook B, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. J Am Acad Dermatol. 2017;76(5):818-825.e3.


Giselle Prado MD